Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure

Ohtsuki, Masatsugu; Morimoto, Shinichiro; Izawa, Hideo; Ismail, Tevfik F; Ishibashi‐Ueda, Hatsue; Kato, Yasuchika; Horii, Taiko; Isomura, Tadashi; Suma, Hisayoshi; Nomura, Masatoshi; Kurahashi, Hiroki

doi:10.1016/j.ijcard.2009.11.057

Cited by 42 publications

(36 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier, a study from Huentelman et al (2005) found that ACE2 overexpression induced by intracardiac injection of a lentiviral vector encoding the mouse ACE2 attenuated the development of Ang II-induced cardiac hypertrophy and fibrosis. Additional studies agree with the conclusion that ACE2 counteracts cardiac remodeling induced by myocardial injury, renal hypertension, and heart failure, as well as retarding the progression of atherosclerosis and vascular injury (Burgelova et al, 2009; Burrell et al, 2005; Crackower et al, 2002; Diez-Freire et al, 2006; Dong et al, 2008; Epelman et al, 2008; Ferrario, 2005; Ferrario et al, 2005a; Goulter et al, 2004; Grobe et al, 2007a, 2007b; Hamming et al, 2008; Heeneman et al, 2007; Hu et al, 2007; Igase et al, 2005, 2008; Ji et al, 2008; Kaiqiang et al, 2009; Kassiri et al, 2009; Lovren et al, 2008; Ohtsuki et al, 2010; Pan et al, 2007; Sluimer et al, 2008; Trask et al, 2010; Varagic et al, 2010; Velkoska et al, 2010; Yamamoto et al, 2006; Zulli et al, 2006). These findings demonstrate that ACE2 plays a central role in balancing the pressor and proliferative activity of the ACE/Ang II/AT 1 receptor axis.…”

Section: Angiotensin-converting Enzyme 2 As a Component Of The Ansupporting

confidence: 69%

“…ACE2 is widely distributed in many tissues with higher levels in the heart, kidney, and testis (Batlle et al, 2006, 2008; Ferrario & Varagic, 2010; Ferrario et al, 2005a, 2005b; Gembardt et al, 2005; Hamming et al, 2004, 2008; Ohtsuki et al, 2010; Oudit et al, 2006). Our studies showed that ACE2-dependent Ang-(1–7) formation from Ang II was significantly higher from the heart of hypertensive rats as compared to normal rat heart (Trask et al, 2007).…”

Section: Angiotensin-converting Enzyme 2 As a Component Of The Anmentioning

confidence: 99%

See 1 more Smart Citation

Advances in the Renin Angiotensin System

Ferrario

Ahmad²,

Joyner³

et al. 2010

Advances in Pharmacology

View full text Add to dashboard Cite

The contribution of the renin angiotensin system to physiology and pathology is undergoing a rapid reconsideration of its mechanisms from emerging new concepts implicating angiotensin-converting enzyme 2 and angiotensin-(1–7) as new elements negatively influencing the vasoconstrictor, trophic, and pro-inflammatory actions of angiotensin II. This component of the system acts to oppose the vasoconstrictor and proliferative effects on angiotensin II through signaling mechanisms mediated by the mas receptor. In addition, a reduced expression of the vasodepressor axis composed by angiotensin-converting enzyme 2 and angiotensin-(1–7) may contribute to the expression of essential hypertension, the remodeling of heart and renal function associated with this disease, and even the physiology of pregnancy and the development of eclampsia.

show abstract

Section: Angiotensin-converting Enzyme 2 As a Component Of The Ansupporting

confidence: 69%

Section: Angiotensin-converting Enzyme 2 As a Component Of The Anmentioning

confidence: 99%

Advances in the Renin Angiotensin System

Ferrario

Ahmad²,

Joyner³

et al. 2010

Advances in Pharmacology

View full text Add to dashboard Cite

show abstract

“…On the other side, increased ACE2 mRNA, protein, and activity were reported in failing human hearts (24–27) and several experimental models of myocardial infarction (16;25). Moreover, ACE2 activity in plasma of heart failure patients increased as well and correlates with unfavorable clinical outcomes (6;28).…”

Section: Ace2 and Cardiac Diseasementioning

confidence: 99%

ACE2: Angiotensin II/Angiotensin-(1–7) Balance in Cardiac and Renal Injury

et al. 2014

View full text Add to dashboard Cite

Our current recognition of the renin-angiotensin system is more convoluted than originally thought due to the discovery of multiple novel enzymes, peptides, and receptors inherent to this interactive biochemical cascade. Over the last decade angiotensin converting enzyme 2 (ACE2) has emerged as a key player in the pathophysiology of hypertension and cardiovascular and renal disease due to its pivotal role in metabolizing vasoconstrictive/hypertrophic/proliferative angiotensin II into favorable angiotensin-(1-7). This review addresses a considerable advancement in research on the role of tissue ACE2 in development and progression of hypertension and cardiorenal injury. We also summarize the results from recent clinical and experimental studies suggesting that serum or urine soluble ACE2 may serve as a novel biomarker or independent risk factor relevant for diagnosis and prognosis of cardiorenal disease. Recent proceedings on novel therapeutic approaches to enhance ACE2/angiotensin-(1-7) axis are also reviewed.

show abstract

“…Interestingly, there was a strong relationship between the amount of ACE2 gene expression and the severity of LV remodeling determined by LV dimensions [31], suggesting that ACE2 expression could be activated as an adaptive compensatory mechanism to militate against LV remodeling. However, ACE2 expression did not correlate with either LV ejection fraction nor plasma BNP levels, implying that such compensatory increased expression of ACE2 may be insufficient to counter pathologic processes as disease progressed [31]. …”

Section: Role Of Ace2 In Cardiac Remodeling and Systolic Dysfunction mentioning

confidence: 99%

Angiotensin-Converting Enzyme 2 as a Therapeutic Target for Heart Failure

Chamsi-Pasha

Shao

Tang

2013

Curr Heart Fail Rep

106

View full text Add to dashboard Cite

The renin-angiotensin system (RAS) plays a major role in the pathophysiology of cardiovascular disorders. Angiotensin II (Ang-II), the final product of this pathway, is known for its vasoconstrictive and proliferative effects. Angiotensin-converting enzyme 2 (ACE2), a newly discovered homolog of ACE, plays a key role as the central negative regulator of the RAS. It diverts the generation of vasoactive Ang-II into the vasodilatory and growth inhibiting peptide angiotensin(1-7) [Ang(1-7)], thereby providing counter-regulatory responses to neurohormonal activation. There is substantial experimental evidence evaluating the role of ACE2/Ang(1-7) in hypertension, heart failure, and atherosclerosis. In this review, we aim to focus on the conceptual facts of the ACE2-Ang(1-7) axis with regards to clinical implications and therapeutic targets in cardiovascular disorders, with emphasis on the potential therapeutic role in cardiovascular diseases.

show abstract

Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure

Cited by 42 publications

References 12 publications

Advances in the Renin Angiotensin System

Advances in the Renin Angiotensin System

ACE2: Angiotensin II/Angiotensin-(1–7) Balance in Cardiac and Renal Injury

Angiotensin-Converting Enzyme 2 as a Therapeutic Target for Heart Failure

Contact Info

Product

Resources

About